Volume | 436,098 |
|
|||||
News | - | ||||||
Day High | 0.29 | Low High |
|||||
Day Low | 0.28 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Dare Bioscience Inc | DARE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.29 | 0.28 | 0.29 | 0.286 | 0.2973 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
720 | 436,098 | $ 0.2873415 | $ 125,309 | - | 0.27 - 1.10 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:36:15 | 30 | $ 0.305 | USD |
Dare Bioscience Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
28.58M | 98.56M | - | 2.81M | -30.16M | -0.31 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Dare Bioscience News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DARE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.46 | 0.4801 | 0.28 | 0.285478 | 1,248,306 | -0.1445 | -31.41% |
1 Month | 0.499 | 0.5599 | 0.28 | 0.3540183 | 488,855 | -0.1835 | -36.77% |
3 Months | 0.3216 | 0.5899 | 0.28 | 0.4271573 | 450,163 | -0.0061 | -1.90% |
6 Months | 0.44 | 0.5899 | 0.27 | 0.3712106 | 510,714 | -0.1245 | -28.30% |
1 Year | 1.00 | 1.10 | 0.27 | 0.5037629 | 381,091 | -0.6845 | -68.45% |
3 Years | 1.53 | 2.51 | 0.27 | 1.64 | 1,828,276 | -1.21 | -79.38% |
5 Years | 1.02 | 3.85 | 0.27 | 1.66 | 1,479,770 | -0.7045 | -69.07% |
Dare Bioscience Description
Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. |